| Antisense Oligonucleotides for the Treatment of Dyslipidemia. | |
| | |
MedLine Citation:
|
PMID: 21418033 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
New studies further demonstrate that lowering low-density lipoprotein (LDL)-cholesterol, at least with the use of statins, decreases the risk of cardiovascular disease (CVD). Subsequently national and international guidelines have set target levels for LDL-cholesterol that are progressively lower, making the likelihood of patients attaining them progressively more limited, even with the use of all currently available medications. Thus, there is a clear need for new therapeutic approaches to lower LDL-cholesterol. Antisense oligonucleotides (ASO) represent a new paradigm for the discovery of potentially powerful and selective drugs with a mechanism of action based on the concept of base-pair hybridizazion as described by Watson and Crick, resulting in decreased production of target proteins. In mouse and human genetic models it has been shown that decreasing hepatic apolipoprotein B-100 (ApoB-100) as well as proprotein convertase subtilisin-like/kexin type 9 (PCSK9) production is associated with lower circulating LDL-cholesterol levels. Purpose of this review is to discuss the available data on the effects of various ASO used for the treatment of dyslipidemia, with the main focus on ASO against ApoB-100, the most advanced in clinical development, and on PCSK9. |
| | |
Authors:
|
I Gouni-Berthold; H K Berthold |
Related Documents
:
|
12324203 - Diet and lifestyle variables as risk factors for chronic renal failure in pet cats. 10679813 - Dietary regulation and localization of apoptosis cascade proteins in the colonic crypt. 19892133 - Chapter 30: historical aspects of the major neurological vitamin deficiency disorders: ... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-3-22 |
Journal Detail:
|
Title: Current pharmaceutical design Volume: - ISSN: 1873-4286 ISO Abbreviation: - Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-3-22 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9602487 Medline TA: Curr Pharm Des Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Internal Medicine II, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany. ioanna.berthold@uni-koeln.de. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Plant Sterols and Stanols in the Treatment of Dyslipidemia: New Insights into Targets and Mechanisms...
Next Document: Lipid-Lowering Drug Therapy in Elderly Patients.